Habibipour Leila, Sadeghi Mahboubeh, Raghibi Alireza, Sanadgol Nima, Mohajeri Khorasani Amirhossein, Mousavi Pegah
Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
Department of Medical Genetics, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
Cancer Med. 2025 Apr;14(8):e70836. doi: 10.1002/cam4.70836.
Nod-like receptor family pyrin domain containing 1 (NLRP1) serves as the central component of the inflammasome complex and has emerged as a potential contributor to cancer development. Despite accumulating evidence, a comprehensive assessment of NLRP1 across various cancer types has yet to be undertaken.
Several databases have evaluated NLRP1 expression across various cancer types in The Cancer Genome Atlas (TCGA). Additionally, studies have investigated the correlation between NLRP1 and various survival metrics, infiltration of cancer-associated fibroblasts, genetic alterations, drug sensitivity, and promoter methylation. Furthermore, research has explored the potential roles of NLRP1 and its interactions with other proteins.
Our analysis revealed decreased expression of NLRP1 in BLCA, BRCA, KICH, LUAD, LUSC, PRAD, and UCEC tumor tissues compared to normal tissues. We identified a significant correlation between NLRP1 expression and various cancer survival parameters, genetic mutations, and immune infiltration of cancer-associated fibroblasts. Furthermore, we observed that NLRP1 expression is regulated by promoter DNA methylation in ESCA. Abnormal expression of NLRP1 was associated with decreased sensitivity to multiple anti-tumor drugs and small compounds. NLRP1 was found to be involved in pathways associated with T cell receptors and chemokines.
Reduced NLRP1 expression contributes to cancer progression and holds potential as a crucial biomolecular marker for diagnostic, prognostic, and personalized therapeutic interventions across different malignancies.
含吡啉结构域的NOD样受体家族成员1（NLRP1）是炎性小体复合物的核心成分，已成为癌症发展的潜在因素。尽管证据不断积累，但尚未对NLRP1在各种癌症类型中的情况进行全面评估。
多个数据库评估了癌症基因组图谱（TCGA）中各种癌症类型的NLRP1表达情况。此外，研究还调查了NLRP1与各种生存指标、癌症相关成纤维细胞浸润、基因改变、药物敏感性和启动子甲基化之间的相关性。此外，研究还探索了NLRP1的潜在作用及其与其他蛋白质的相互作用。
我们的分析显示，与正常组织相比，BLCA、BRCA、KICH、LUAD、LUSC、PRAD和UCEC肿瘤组织中NLRP1的表达降低。我们发现NLRP1表达与各种癌症生存参数、基因突变以及癌症相关成纤维细胞的免疫浸润之间存在显著相关性。此外，我们观察到ESCA中NLRP1的表达受启动子DNA甲基化调控。NLRP1的异常表达与对多种抗肿瘤药物和小分子化合物的敏感性降低有关。发现NLRP1参与与T细胞受体和趋化因子相关的信号通路。
NLRP1表达降低促进癌症进展，有望成为不同恶性肿瘤诊断、预后和个性化治疗干预的关键生物分子标志物。
